Selecta Biosciences, Inc.
SELB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 51.7% | -72.9% | -94.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | 0% | 0% | 88.2% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -7,808.8% | -7,319.1% | 0% | -189.5% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | -147.7% |
| EPS Diluted | -1.38 | 0.5 | -0.11 | -0.2 |
| % Growth | -376% | 554.5% | 45% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |